|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary Brain and Central Nervous System
Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol. 17
Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reifenberger G, Wirsching HG,
Knobbe-Thomsen CB and Weller M: Advances in the molecular genetics
of gliomas - implications for classification and therapy. Nat Rev
Clin Oncol. 14:434–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perri E, Parakh S and Atkin J: Protein
disulphide isomerases: Emerging roles of PDI and ERp57 in the
nervous system and as therapeutic targets for ALS. Expert Opin Ther
Targets. 21:37–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zou Q, Yang ZL, Yuan Y, Li JH, Liang LF,
Zeng GX and Chen SL: Clinicopathological features and CCT2 and
PDIA2 expression in gallbladder squamous/adenosquamous carcinoma
and gallbladder adenocarcinoma. World J Surg Oncol. 11:1432013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choe MH, Min JW, Jeon HB, Cho DH, Oh JS,
Lee HG, Hwang SG, An S, Han YH and Kim JS: ERp57 modulates STAT3
activity in radioresistant laryngeal cancer cells and serves as a
prognostic marker for laryngeal cancer. Oncotarget. 6:2654–2666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung H, Cho H, Perry C, Song J, Ylaya K,
Lee H and Kim JH: Downregulation of ERp57 expression is associated
with poor prognosis in early-stage cervical cancer. Biomarkers.
18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takata H, Kudo M, Yamamoto T, Ueda J,
Ishino K, Peng WX, Wada R, Taniai N, Yoshida H, Uchida E, et al:
Increased expression of PDIA3 and its association with cancer cell
proliferation and poor prognosis in hepatocellular carcinoma. Oncol
Lett. 12:4896–4904. 2016.PubMed/NCBI
|
|
9
|
Negroni L, Taouji S, Arma D,
Pallares-Lupon N, Leong K, Beausang LA, Latterich M, Bossé R,
Balabaud C, Schmitter JM, et al: Integrative quantitative
proteomics unveils proteostasis imbalance in human hepatocellular
carcinoma developed on nonfibrotic livers. Mol Cell Proteomics.
13:3473–3483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shen H, Huang J, Pei H, Zeng S, Tao Y,
Shen L, Zeng L and Zhu H: Comparative proteomic study for profiling
differentially expressed proteins between Chinese left- and
right-sided colon cancers. Cancer Sci. 104:135–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia W, Zhuang J, Wang G, Ni J, Wang J and
Ye Y: P4HB promotes HCC tumorigenesis through downregulation of
GRP78 and subsequent upregulation of epithelial-to-mesenchymal
transition. Oncotarget. 8:8512–8521. 2017.PubMed/NCBI
|
|
12
|
Da Costa GG, Gomig TH, Kaviski R, Santos
Sousa K, Kukolj C, De Lima RS, De Andrade Urban C, Cavalli IJ and
Ribeiro EM: Comparative proteomics of tumor and paired normal
breast tissue highlights potential biomarkers in breast cancer.
Cancer Genomics Proteomics. 12:251–261. 2015.PubMed/NCBI
|
|
13
|
Gromov P, Gromova I, Bunkenborg J, Cabezon
T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F and
Celis JE: Up-regulated proteins in the fluid bathing the tumour
cell microenvironment as potential serological markers for early
detection of cancer of the breast. Mol Oncol. 4:65–89. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun L, Hui AM, Su Q, Vortmeyer A,
Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey
R, et al: Neuronal and glioma-derived stem cell factor induces
angiogenesis within the brain. Cancer Cell. 9:287–300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Costa BM, Smith JS, Chen Y, Chen J,
Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, et
al: Reversing HOXA9 oncogene activation by PI3K inhibition:
Epigenetic mechanism and prognostic significance in human
glioblastoma. Cancer Res. 70:453–462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Freije WA, Castro-Vargas FE, Fang Z,
Horvath S, Cloughesy T, Liau LM, Mischel PS and Nelson SF: Gene
expression profiling of gliomas strongly predicts survival. Cancer
Res. 64:6503–6510. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawaguchi A, Yajima N, Tsuchiya N, Homma
J, Sano M, Natsumeda M, Takahashi H, Fujii Y, Kakuma T and Yamanaka
R: Gene expression signature-based prognostic risk score in
patients with glioblastoma. Cancer Sci. 104:1205–1210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets - update. Nucleic Acids Res. 41(D1): D991–D995.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R,
Yan W and You Y: IDH1/2 mutation status combined with Ki-67
labeling index defines distinct prognostic groups in glioma.
Oncotarget. 6:30232–30238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
England B, Huang T and Karsy M: Current
understanding of the role and targeting of tumor suppressor p53 in
glioblastoma multiforme. Tumour Biol. 34:2063–2074. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee
NP, Day PJ, Lui WM, Fung CF and Leung GK: Inhibition of prolyl
4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide
resistance in malignant glioma via the endoplasmic reticulum stress
response (ERSR) pathways. Neuro Oncol. 15:562–577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li S, Li C, Ryu HH, Lim SH, Jang WY and
Jung S: Bacitracin inhibits the migration of U87-MG glioma cells
via interferences of the integrin outside-in signaling pathway. J
Korean Neurosurg Soc. 59:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Binet F and Sapieha P: ER Stress and
Angiogenesis. Cell Metab. 22:560–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bechtel TJ and Weerapana E: From structure
to redox: The diverse functional roles of disulfides and
implications in disease. Proteomics. 17:16003912017. View Article : Google Scholar
|
|
26
|
Xu S, Sankar S and Neamati N: Protein
disulfide isomerase: A promising target for cancer therapy. Drug
Discov Today. 19:222–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Na KS, Park BC, Jang M, Cho S, Lee DH,
Kang S, Lee CK, Bae KH and Park SG: Protein disulfide isomerase is
cleaved by caspase-3 and −7 during apoptosis. Mol Cells.
24:261–267. 2007.PubMed/NCBI
|
|
28
|
Zhao G, Lu H and Li C: Proapoptotic
activities of protein disulfide isomerase (PDI) and PDIA3 protein,
a role of the Bcl-2 protein Bak. J Biol Chem. 290:8949–8963. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lwin ZM, Yip GW, Chew FT and Bay BH:
Downregulation of ER60 protease inhibits cellular proliferation by
inducing G1/S arrest in breast cancer cells in vitro. Anat Rec
(Hoboken). 295:410–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thongwatchara P, Promwikorn W, Srisomsap
C, Chokchaichamnankit D, Boonyaphiphat P and Thongsuksai P:
Differential protein expression in primary breast cancer and
matched axillary node metastasis. Oncol Rep. 26:185–191.
2011.PubMed/NCBI
|
|
31
|
Khan MM, Simizu S, Suzuki T, Masuda A,
Kawatani M, Muroi M, Dohmae N and Osada H: Protein disulfide
isomerase-mediated disulfide bonds regulate the gelatinolytic
activity and secretion of matrix metalloproteinase-9. Exp Cell Res.
318:904–914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kullmann M, Kalayda GV, Hellwig M, Kotz S,
Hilger RA, Metzger S and Jaehde U: Assessing the contribution of
the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin
resistance. J Inorg Biochem. 153:247–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu S, Butkevich AN, Yamada R, Zhou Y,
Debnath B, Duncan R, Zandi E, Petasis NA and Neamati N: Discovery
of an orally active small-molecule irreversible inhibitor of
protein disulfide isomerase for ovarian cancer treatment. Proc Natl
Acad Sci USA. 109:pp. 16348–16353. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caorsi C, Niccolai E, Capello M, Vallone
R, Chattaragada MS, Alushi B, Castiglione A, Ciccone G, Mautino A,
Cassoni P, et al: Protein disulfide isomerase A3-specific Th1
effector cells infiltrate colon cancer tissue of patients with
circulating anti-protein disulfide isomerase A3 autoantibodies.
Transl Res. 171:17–28 e11-12. 2016. View Article : Google Scholar : PubMed/NCBI
|
